

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**In re Application of:**

Beyaert et al.

**Serial No.:** Not yet assigned

**Filed:** October 8, 2003

**For:** NOVEL INHIBITORS OF NF- B  
ACTIVATION

**Confirmation No.:** Not yet assigned

**Examiner:** Unknown

**Group Art Unit:** Unknown

**Attorney Docket No.:** 2676-4554.1US

**NOTICE OF EXPRESS MAILING**

Express Mail Mailing Label Number: EV 326918765 US

Date of Deposit with USPS: October 8, 2003

Person making Deposit: Christopher Haughton

**INFORMATION DISCLOSURE STATEMENT**

Mail Stop PATENT APPLICATION  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO/SB/08A be considered by the Examiner and made of record. Copies of the listed documents are enclosed pursuant to 37 C.F.R. § 1.98(a).

In accordance with 37 C.F.R. § 1.97(g) and (h), filing of this Information Disclosure Statement is not to be construed as a representation that a search has been made or an admission that the information cited herein is, or is considered to be, material to patentability as defined in

37 C.F.R. § 1.56(b). Further, no representation is made by Applicants herein that no other possible material information as defined in 37 C.F.R. § 1.56(b) exists.

Foreign Patent Documents

<u>Document No.</u>	<u>Publication Date</u>	<u>Patentee</u>
WO 97/37016 #	10/09/1997	PCT

Other Documents

DE VALCK et al., "A20, an inhibitor of cell death, self-associates by its zinc finger domain," 384 FEBS Letters 61-64 (1996). #

FUKUSHI, M., "Homo sapiens mRNA for HIV-1, Nef-associated factor 1 beta (Naf1 beta)," EMHUM DATABASE ENTRY HSA011896, ACCESSION NUMBER AJ011896, October 14, 1998, XP002124741. #

FUKUSHI, M., et al., "NAF1 alpha protein (KIAA0113 protein)," TREMBL DATABASE ENTRY A15025, ACCESSION NUMBER Q15025, November 1, 1996, XP02124740. #

HENDRICK, B.D., et al., "An X-linked homologue of the autosomal imprinted gene NF127 escapes X chromosome inactivation," EMHUM DATABASE ENTRY HS4131510; ACCESSION NUMBER U41315, May 19, 1996, XP002125387. #

HEYINCK et al., "The Zinc Finger Protein A20 Inhibits TNF-induced NF-kB-dependent Gene Expression by interfering with an RIP- or TRAF2-mediated Transactivation Signal and Directly Binds to a Novel NF-kB-inhibiting Protein ABIN," 145 THE JOURNAL OF CELL BIOLOGY 1471-1482 (1999). #

MIYAJIMA, N., et al., "Human mRNA for KIAA 0133 gene, partial coding sequence," EMHUM DATABASE ENTRY HSORFA2, ACCESSION NUMBER D30755, May 21, 1994, XP002124739. #

NOMURA et al., "mRNA for ORF, partial CDS (fragment)," TRHUM DATABASE ENTRY Q15025; November 1, 1996, ACCESSION NUMBER Q15025, XP002080989. #

SONG et al., "The tumor necrosis factor-inducible zinc finger protein A20 interacts with TRAF1/TRAF2 and inhibits NF-kB activation," 93 PROC. NATL. ACAD. SCI. USA 6721-6725 (1996). #

Other Documents

YEN, R.W.C., et al., "DNA-methyltransferase," SWISSPROT DATABASE ENTRY  
MTDM\_HUMAN; May 1, 1992, ACCESSION NUMBER P26358, XP002080990. #

PCT International Search Report, PCT/BE99/00055, dated December 31, 1999 (9 pages). #

PCT International Preliminary Examination Report, PCT/BE99/00055, dated August 10, 2000. #

YAMAMOTO et al., "Therapeutic potential of inhibition of the NF-kappaB pathway in the  
treatment of inflammation and cancer," 107(2) J. CLIN. INVEST. 135-142 (January  
2001). #

GHOSH, et al., "Missing Pieces in the NF-kappaB Puzzle," 109 CELL S81-S96 (April 2002). #

BALDWIN, A.S., "The transcription factor NF-kappaB and human disease," 107(1) J. CLIN.  
INVEST. 3-6 (January 2001). #

NGO et al., "Computational Complexity, Protein Structure Prediction and the Levinthal  
Paradox," The Protein Folding Problem and Tertiary Structure, Merz et al. ed.,  
pages 14-16 (1994). #

ZHANG, et al., "Environment-dependent residue contact energies for proteins," 97(6) PROC.  
NATL. SCI. 2550-2555 (March 2000). #

FUKUSHI et al., (November 1, 1996) Acc. No. Q15025, SPTREMBL\_17 database, GenCore  
Version 4.5, Accessed May 8, 2002. #

GUPTA, et al. (March 1, 2001) Acc. No. Q9H1J3, SPTREMBL\_17, GenCore Version 4.5,  
Accessed May 8, 2002. #

HEYNINCK, K., et al., "Structure-function analysis of the A20-binding inhibitor of NF-kB  
activation, ABIN-1," 536 FEBS LETTERS 135-140 (2003).

#Pursuant to 37 C.F.R. § 1.98(d), copies of the previously identified patents are not being provided since they were previously cited by or submitted to the  
Office in the following prior application:

Serial No.: 09/702,953

Filed: October 31, 2000

For: NOVEL INHIBITORS OF NF- B ACTIVATION, which application is being relied upon for an earlier filing date under 35 U.S.C. § 120.

**Attorney Docket No. 2676-4554.1US**

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56 & 1.175, Applicants offer hereby identifies the following listed copending applications naming the same inventor(s):

Attorney Docket No.: Serial No.: Filing Date: Title:	2676-4359US 09/553,789 April 21, 2000 INDUCIBLE CELLULAR IMMUNITY THROUGH ACTIVATION OF TH1 AND SUPPRESSION OF TH2 RESPONSES BY MACROPHAGES
Attorney Docket No.: Serial No.: Filing Date: Title:	2676-4661US 09/764,803 January 17, 2001 NEW CASPASE HOMOLOGUE
Attorney Docket No.: Serial No.: Filing Date: Title:	2676-4661.1US 10/349,496 January 21, 2003 NEW CASPASE HOMOLOGUE
Attorney Docket No.: Serial No.: Filing Date: Title:	2676-4779US 09/838,718 April 19, 2001 USE OF A CYTOKINE-PRODUCING LACTOCOCCUS STRAIN TO TREAT COLITIS
Attorney Docket No.: Serial No.: Filing Date: Title:	2676-4976US 09/915,060 July 25, 2001 INTERNAL RIBOSOME ENTRY SITE, VECTOR CONTAINING SAME AND USES THEREOF
Attorney Docket No.: Serial No.: Filing Date: Title:	2676-5969US 10/415,506 April 28, 2003 METHODS AND MEANS FOR THE DEOLIGOMERISATION OF OLIGOMERIC MOLECULES

This Information Disclosure Statement is filed within three (3) months of the filing date of the above-identified application, and no certification pursuant to 37 C.F.R. § 1.97(c) or a fee pursuant to 37 C.F.R. § 1.17(p) is required.

Respectfully submitted,



G. Scott Dorland, Ph.D.  
Registration No. 51,622  
Attorney for Applicants  
TRASKBRITT, P.C.  
P.O. Box 2550  
Salt Lake City, Utah 84110-2550  
Telephone: 801-532-1922

Date: October 8, 2003  
GSD/jml

Enclosures: Form PTO/SB/08A  
Cited Documents

Document in ProLaw

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet

1

of

3

**Complete if Known**

Application Number

Not yet assigned
------------------

Filing Date

October 8, 2003

First Named Inventor

Beyaert et al.

Group Art Unit

Unknown

Examiner Name

Unknown

Attorney Docket Number

2676-4554.1US

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner  
Signature**

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT***(use as many sheets as necessary)*

Sheet 2 of 3

**Complete if Known**

Application Number	Not yet assigned
Filing Date	October 8, 2003
First Named Inventor	Beyaert et al.
Group Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	2676-4554 IUS

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		DE VALCK et al., "A20, an inhibitor of cell death, self-associates by its zinc finger domain," 384 FEBS Letters 61-64 (1996). #	
		FUKUSHI, M., "Homo sapiens mRNA for HIV-1, Nef-associated factor 1 beta (Naf1 beta);: EMHUM DATABASE ENTRY HSA011896, ACCESSION NUMBER AJ011896, October 14, 1998, XP002124741. #	
		FUKUSHI, M., et al., "NAF1 alpha protein (KIAA0113 protein)," TREMBL DATABASE ENTRY A15025, ACCESSION NUMBER Q15025, November 1, 1996, XP02124740. #	
		HENDRICK, B.D., et al., "An X-linked homologue of the autosomal imprinted gene NF127 escapes X chromosome inactivation," EMHUM DATABASE ENTRY HS4131510; ACCESSION NUMBER U41315, May 19, 1996, XP002125387. #	
		HEYININCK et al., "The Zinc Finger Protein A20 Inhibits TNF-induced NF-kB-dependent Gene Expression by interfering with an RIP- or TRAF2-mediated Transactivation Signal and Directly Binds to a Novel NF-kB-inhibiting Protein ABIN," 145 THE JOURNAL OF CELL BIOLOGY 1471-1482 (1999). #	
		MIYAJIMA, N., et al., "Human mRNA for KIAA 0133 gene, partial coding sequence," EMHUM DATABASE ENTRY HSORFA2, ACCESSION NUMBER D30755, May 21, 1994, XP002124739. #	
		NOMURA et al., "mRNA for ORF, partial CDS (fragment)," TRHUM DATABASE ENTRY Q15025; November 1, 1996, ACCESSION NUMBER Q15025, XP002080989. #	
		SONG et al., "The tumor necrosis factor-inducible zinc finger protein A20 interacts with TRAF1/TRAFF2 and inhibits NF-kB activation," 93 PROC. NATL. ACAD. SCI. USA 6721-6725 (1996). #	
		YEN, R.W.C., et al., "DNA-methyltransferase," SWISSPROT DATABASE ENTRY MTDM_HUMAN; May 1, 1992, ACCESSION NUMBER P26358, XP002080990. #	
		PCT International Search Report, PCT/BE99/00055, dated December 31, 1999 (9 pages). #	
		PCT International Preliminary Examination Report, PCT/BE99/00055, dated August 10, 2000. #	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO

NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

3

of

3

**Complete if Known**

Application Number	Not yet assigned
Filing Date	October 8, 2003
First Named Inventor	Beyaert et al.
Group Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	2676-4554 IUS

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		YAMAMOTO et al., "Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer," 107(2) J. CLIN. INVEST. 135-142 (January 2001). #	
		GHOSH, et al., "Missing Pieces in the NF-kappaB Puzzle," 109 CELL S81-S96 (April 2002). #	
		BALDWIN, A.S., "The transcription factor NF-kappaB and human disease," 107(1) J. CLIN. INVEST. 3-6 (January 2001). #	
		NGO et al., "Computational Complexity, Protein Structure Prediction and the Levinthal Paradox," The Protein Folding Problem and Tertiary Structure, Merz et al. ed., pages 14-16 (1994). #	
		ZHANG, et al., "Environment-dependent residue contact energies for proteins," 97(6) PROC. NATL. SCI. 2550-2555 (March 2000). #	
		FUKUSHI et al., (November 1, 1996) Acc. No. Q15025, SPTREMBL_17 database, GenCore Version 4.5, Accessed May 8, 2002. #	
		GUPTA, et al. (March 1, 2001) Acc. No. Q9H1J3, SPTREMBL_17, GenCore Version 4.5, Accessed May 8, 2002. #	
		HEYININCK, K., et al., "Structure-function analysis of the A20-binding inhibitor of NF- $\kappa$ B activation, ABIN-1," 536 FEBS LETTERS 135-140 (2003).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

#Pursuant to 37 C.F.R. § 1.98(d), copies of the previously identified patents are not being provided since they were previously cited by or submitted to the Office in the following prior application:

Serial No.: 09/702,953

Filed: October 31, 2000

For: NOVEL INHIBITORS OF NF- $\kappa$ B ACTIVATION, which application is being relied upon for an earlier filing date under 35 U.S.C. § 120.

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.